1,150 results on '"Brunner, Hermine"'
Search Results
102. Catch-Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial
103. Half-Life and Safety of Canakinumab in Pediatric Patients: Comment on the Article by Ilowite et al
104. Cost-effectiveness analysis of ED decision making in patients with non–high-risk heart failure
105. International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis
106. Cross-cultural adaptation and initial validation of the Brazilian-Portuguese version of the pediatric automated neuropsychological assessment metrics.
107. Efficacy and safety of tocilizumab for polyarticular-course juvenile idiopathic arthritis in the open-label two-year extension of a phase III trial
108. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
109. 2021 DORIS definition of remission in SLE: final recommendations from an international task force.
110. 2021 DORIS definition of remission in SLE:Final recommendations from an international task force
111. The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease
112. Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells
113. A156: Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid and Response to Therapy in Childhood-Onset Systemic Lupus Erythematosus
114. A148: A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results
115. Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus
116. Biomarkers for renal disease in childhood
117. The impact and implications of neuropsychiatric systemic lupus erythematosus in adolescents
118. OPINION: The landscape of comparative effectiveness research in rheumatology
119. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis
120. Performance of the New 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults
121. Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis
122. Identification of a urinary proteomic signature for lupus nephritis in children
123. School Support and Functioning for Children with Juvenile Rheumatic Diseases
124. Pain, Fatigue, Family Functioning, and Attitude Toward Illness in Children with Juvenile Rheumatic Diseases
125. Additional file 1 of Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study
126. Additional file 2 of Cerebral microvascular and microstructural integrity is regionally altered in patients with systemic lupus erythematosus
127. Additional file 2 of Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study
128. Additional file 1 of Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
129. MOESM1 of The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis
130. Understanding the biology and use of anti-TNF agents in JIA – interim results
131. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
132. Developing consensus treatment plans for proliferative lupus nephritis in childhood-onset systemic lupus erythematous
133. Use of immunosuppressive medications and prevalence of disability among patients with pediatric systemic lupus erythematosus: initial analysis of the CARRAnet registry
134. Biologics in paediatric rheumatic diseases
135. Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results
136. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.
137. Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis
138. Achieving consensus on quality indicators (QI) for pediatric Systemic Lupus Erythematosus (pSLE)
139. Defining clinical remission and clinically inactive disease in juvenile systemic lupus erythematosus (jSLE)
140. Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis
141. PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing
142. Characterization Of Changes In Gene Expression and Inflammatory Proteins In Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy.: 1692
143. Pharmacokinetics and pharmacodynamics of long-term tocilizumab therapy in polyarticular juvenile idiopathic arthritis.: 173.
144. Pharmacokinetics and pharmacodynamics of long-term tocilizumab therapy in patients with systemic juvenile idiopathic arthritis.: 172.
145. Brain Morphometric Changes Associated With Childhood-Onset Systemic Lupus Erythematosus and Neurocognitive Deficit
146. Neuroinflammation and Pediatric Lupus
147. Contributors
148. List of Contributors
149. SLE in Children
150. TRIAL DESIGN, MEASUREMENT, AND ANALYSIS OF CLINICAL INVESTIGATIONS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.